[HTML][HTML] Outcome measures in clinical trials for multiple sclerosis
CEP van Munster, BMJ Uitdehaag - CNS drugs, 2017 - Springer
Due to the heterogeneous nature of the disease, it is a challenge to capture disease activity
of multiple sclerosis (MS) in a reliable and valid way. Therefore, it can be difficult to assess …
of multiple sclerosis (MS) in a reliable and valid way. Therefore, it can be difficult to assess …
Outcome Measures in Clinical Trials for Multiple Sclerosis
CEP Munster, BMJ Uitdehaag - CNS Drugs, 2017 - infona.pl
Due to the heterogeneous nature of the disease, it is a challenge to capture disease activity
of multiple sclerosis (MS) in a reliable and valid way. Therefore, it can be difficult to assess …
of multiple sclerosis (MS) in a reliable and valid way. Therefore, it can be difficult to assess …
Outcome Measures in Clinical Trials for Multiple Sclerosis.
CE van Munster, BM Uitdehaag - CNS Drugs, 2017 - europepmc.org
Due to the heterogeneous nature of the disease, it is a challenge to capture disease activity
of multiple sclerosis (MS) in a reliable and valid way. Therefore, it can be difficult to assess …
of multiple sclerosis (MS) in a reliable and valid way. Therefore, it can be difficult to assess …
[HTML][HTML] Outcome Measures in Clinical Trials for Multiple Sclerosis
CEP van Munster, BMJ Uitdehaag - CNS Drugs, 2017 - ncbi.nlm.nih.gov
Due to the heterogeneous nature of the disease, it is a challenge to capture disease activity
of multiple sclerosis (MS) in a reliable and valid way. Therefore, it can be difficult to assess …
of multiple sclerosis (MS) in a reliable and valid way. Therefore, it can be difficult to assess …
Outcome Measures in Clinical Trials for Multiple Sclerosis
CEP van Munster, BMJ Uitdehaag - CNS drugs, 2017 - pubmed.ncbi.nlm.nih.gov
Due to the heterogeneous nature of the disease, it is a challenge to capture disease activity
of multiple sclerosis (MS) in a reliable and valid way. Therefore, it can be difficult to assess …
of multiple sclerosis (MS) in a reliable and valid way. Therefore, it can be difficult to assess …
[引用][C] Outcome Measures in Clinical Trials for Multiple Sclerosis
CEP van Munster, BMJ Uitdehaag - CNS Drugs, 2017 - cir.nii.ac.jp
Outcome Measures in Clinical Trials for Multiple Sclerosis
CEP van Munster, BMJ Uitdehaag - CNS Drugs, 2017 - search.proquest.com
Due to the heterogeneous nature of the disease, it is a challenge to capture disease activity
of multiple sclerosis (MS) in a reliable and valid way. Therefore, it can be difficult to assess …
of multiple sclerosis (MS) in a reliable and valid way. Therefore, it can be difficult to assess …
[PDF][PDF] Outcome Measures in Clinical Trials for Multiple Sclerosis
CEP van Munster, BMJ Uitdehaag - 2017 - cyberleninka.org
Due to the heterogeneous nature of the disease, it is a challenge to capture disease activity
of multiple sclerosis (MS) in a reliable and valid way. Therefore, it can be difficult to assess …
of multiple sclerosis (MS) in a reliable and valid way. Therefore, it can be difficult to assess …
[PDF][PDF] Outcome Measures in Clinical Trials for Multiple Sclerosis
CEP van Munster, BMJ Uitdehaag - CNS Drugs, 2017 - core.ac.uk
Due to the heterogeneous nature of the disease, it is a challenge to capture disease activity
of multiple sclerosis (MS) in a reliable and valid way. Therefore, it can be difficult to assess …
of multiple sclerosis (MS) in a reliable and valid way. Therefore, it can be difficult to assess …
Outcome Measures in Clinical Trials for Multiple Sclerosis
CEP van Munster, BMJ Uitdehaag - CNS Drugs, 2017 - researchinformation.amsterdamumc …
Due to the heterogeneous nature of the disease, it is a challenge to capture disease activity
of multiple sclerosis (MS) in a reliable and valid way. Therefore, it can be difficult to assess …
of multiple sclerosis (MS) in a reliable and valid way. Therefore, it can be difficult to assess …